Skip to content

Development and Evaluation of an Intelligent Follow-up and Health Management System for Elderly Osteoporosis Patients Based on a Multimodal Large Model

Development and Evaluation of an Intelligent Follow-up and Health Management System for Elderly Osteoporosis Patients Based on a Multimodal Large Model

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117361
Enrollment
Unknown
Registered
2026-01-22
Start date
2026-01-26
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Control Group:Conventional follow-up: telephone follow-up every 3 months, recording medication adherence, symptom and sign changes, lifestyle, diet, exercise, risk assessment, and quality of life. Res
Intervention Group:Comprehensive intervention using the AI follow-up system: Information is pushed to patients via the WeChat mini-program, including effective interventions (phone calls, face-to-face

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 60 years and <= 80 years; 2. Diagnosed with osteoporosis according to the diagnostic criteria specified in the *Chinese Guidelines for the Diagnosis and Treatment of Primary Osteoporosis* (2022 Edit); 3. Availability of a DXA bone density test result from Beijing Hospital within the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Secondary osteoporosis; endocrine diseases affecting bone metabolism (parathyroid diseases, gonadal, adrenal, thyroid diseases, etc.); autoimmune diseases like rheumatoid arthritis; gastrointestinal and renal diseases affecting calcium and vitamin D absorption and metabolism; neuromuscular diseases; malignant diseases like multiple myeloma; various congenital and acquired bone metabolism abnormalities; long-term use of glucocorticoids or other drugs affecting bone metabolism. 2. Inability to use a smartphone or WeChat mini-program for registration and follow-up; 3. Incomplete data. Signed informed consent is required.

Design outcomes

Primary

MeasureTime frame
Percentage change in lumbar spine (L1-L4) bone mineral density (BMD) from baseline at 12 months;

Secondary

MeasureTime frame
Behavioral adherence: Treatment adherence (treatment rate, follow-up rate, medication adherence score, medication possession ratio), disease awareness level (questionnaire survey), adequacy rate of calcium/vitamin D intake, exercise prescription compliance rate, satisfaction score;Clinical outcomes: Pain VAS score, incidence of new vertebral/hip fractures at 12 months, incidence of fall events, quality of life score;Incidence rate of new vertebral/hip fractures;Health economics: Annual per capita medical costs (medications + examinations + hospitalization), physician follow-up time cost (minutes per case);

Countries

China

Contacts

Public ContactDuan Xiaoye

Beijing Hospital

duanxiaoye1992@163.com+86 188 1115 2752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026